



The 2nd International Neuroinflammation Congress and 2nd Student Festival of Neuroscience

Shefa Neuroscience Research Center, Tehran, Iran, 17-19 April, 2018

The Neuroscience Journal of Shefaye Khatam

Volume 6, No. 2, Suppl 1

Oral Presentation

NK Cells as Surrogate Marker for Predicting Treatment Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy

Anne Kathrin Mausberg^{1*}, M. K. Heininger², G. Meyer Zu Horste³, S. Cordes⁴, C. Kleinschnitz¹, B. C. Kieseier², M. Stettner¹

¹University Hospital Essen, Neurology, Essen, Germany

²Heinrich-Heine-University, Neurology, Duesseldorf, Germany

³University of Muenster, Neurology, Muenster, Germany

⁴Charité Berlin, Department of Hematology, Oncology & Tumor Immunology, Berlin/Germany

Published: 17 April, 2018

Abstract

Natural Killer (NK) cells are part of our innate immune system with regulatory and effector functions. Different studies suggest that treatment with intravenous immunoglobulins (IVIg) has an immunomodulatory effect on NK cells. IVIg is a first-line treatment for various autoimmune diseases in particular in chronic inflammatory demyelinating polyneuropathy (CIDP). The lack of predictive markers for IVIg responsiveness in CIDP avoids the early preservation of non-responding patients. Using semi-quantitative PCR and flow cytometry in the peripheral blood of patients with CIDP, we analysed the effects of IVIg on the NK cells and correlated changes with the IVIg responsiveness. IVIg administrations induced a reduction in the expression of several typical NK cell genes. Flow cytometry data revealed that IVIg reduced the cytotoxic CD56dim NK cell population, while regulatory CD56bright NK cells remained almost unaffected or were even increased. Interestingly, the observed effects on NK cells almost exclusively occurred in IVIg responding CIDP patients. Correlation between changes in the NK cell population and treatment efficiency suggests a crucial role for NK cells in the immunomodulatory mechanism of IVIg. Further studies will investigate whether differences in the NK cell status of CIDP patients represent a reliable surrogate marker predicting the outcome of IVIg therapy.

Keywords: NK Cells, Chronic Inflammatory, Demyelinating Polyneuropathy

***Corresponding Author:** Anne Kathrin Mausberg

Email: anne-kathrin.mausberg@uk-essen.de